Table 3.
Treatment-related adverse events reported in >3 patients treated with PF-06647263 Q3W1
| Adverse event n (%) | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Total N = 25 |
|---|---|---|---|---|---|
| Any AE | 1 (4.0) | 11 (44.0) | 8 (32.0) | 4 (16.0)2 | 24 (96.0) |
| Nausea | 12 (48.0) | 3 (12.0) | 1 (4.0) | 0 (0.0) | 16 (64.0) |
| Fatigue | 4 (16.0) | 11 (44.0) | 1 (4.0) | 0 (0.0) | 16 (64.0) |
| Decreased appetite | 5 (20.0) | 7 (28.0) | 0 (0.0) | 0 (0.0) | 12 (48.0) |
| Thrombocytopenia | 2 (8.0) | 4 (16.0) | 2 (8.0) | 3 (12.0) | 11 (44.0) |
| Dysgeusia | 7 (28.0) | 2 (8.0) | 0 (0.0) | 0 (0.0) | 9 (36.0) |
| Diarrhea | 6 (24.0) | 0 (0.0) | 1 (4.0) | 0 (0.0) | 7 (28.0) |
| Mucosal inflammation | 1 (4.0) | 4 (16.0) | 2 (8.0) | 0 (0.0) | 7 (28.0) |
| Skin hyperpigmentation | 6 (24.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) | 7 (28.0) |
| Stomatitis | 3 (12.0) | 2 (8.0) | 2 (8.0) | 0 (0.0) | 7 (28.0) |
| Vomiting | 4 (16.0) | 2 (8.0) | 1 (4.0) | 0 (0.0) | 7 (28.0) |
| Rash | 5 (20.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) | 6 (24.0) |
| Abdominal pain | 1 (4.0) | 4 (16.0) | 0 (0.0) | 0 (0.0) | 5 (20.0) |
| Dry mouth | 4 (16.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) | 5 (20.0) |
| Nail disorder | 5 (20.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (20.0) |
| Anemia | 1 (4.0) | 2 (8.0) | 1 (4.0) | 0 (0.0) | 4 (16.0) |
| Oral candidiasis | 2 (8.0) | 2 (8.0) | 0 (0.0) | 0 (0.0) | 4 (16.0) |
1
No grade 5 AEs were reported.
2
One patient experienced grade 4 neutropenia. AE: adverse event; Q3W: every 3 weeks.